Compare · ABT vs AMRN
ABT vs AMRN
Side-by-side comparison of Abbott Laboratories (ABT) and Amarin Corporation plc (AMRN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and AMRN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 672.3x AMRN ($298.9M).
- ABT has been more active in the news (8 items in the past 4 weeks vs 3 for AMRN).
- ABT has more recent analyst coverage (25 ratings vs 11 for AMRN).
- Company
- Abbott Laboratories
- Amarin Corporation plc
- Price
- $115.06-0.90%
- $14.21+0.28%
- Market cap
- $200.95B
- $298.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 11
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest AMRN
- New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
- Analyst resumed coverage on Amarin with a new price target
- SVP, CFO Fishman Peter L. converted options into 313 units of American Depositary Share and covered exercise/tax liability with 155 units of American Depositary Share, increasing direct ownership by 2% to 7,619 units (SEC Form 4)
- SEC Form 10-Q filed by Amarin Corporation plc
- Amarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition
- Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
- EVP, Chief Scientific Officer Ketchum Steven B converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,887 units of American Depositary Shares, increasing direct ownership by 4% to 42,680 units (SEC Form 4)
- EVP, Chief Operating Officer Keenan David Paul converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,926 units of American Depositary Shares, increasing direct ownership by 15% to 13,470 units (SEC Form 4)
- SVP, CFO Fishman Peter L. converted options into 2,447 units of American Depositary Shares and covered exercise/tax liability with 1,206 units of American Depositary Shares, increasing direct ownership by 20% to 7,461 units (SEC Form 4)
- EVP, Chief Legal Officer Provoost Jonathan converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,264 units of American Depositary Shares, increasing direct ownership by 110% to 4,624 units (SEC Form 4)